Germany's new cost-benefit system gets underway
This article was originally published in Scrip
Executive Summary
Antidepressants and the anti-thrombotic clopidogrel are to be the first drugs to undergo the new cost-benefit assessment method developed by Germany's health technology assessment body IQWiG. However, this new method has failed to impress the pharmaceutical industry.